EQS-News: White Tale: Open letter to the BoD of Clariant

Nachricht vom 19.09.2017 (www.4investors.de) -


EQS Group-News: Dynamics Group AG / Schlagwort(e): Sonstiges

White Tale: Open letter to the BoD of Clariant
19.09.2017 / 07:03
Dr. Rudolf Wehrli
Chairman of the Board of Directors
Dr. Hariolf Kottmann
CEO and Chairman of the Executive Committee
Clariant AG
Rothausstrasse 61
4132 Muttenz 1
Switzerland


Dear Dr. Wehrli, Dr. Kottmann and Members of the Board:

White Tale Holdings ("White Tale"), an investment partnership jointly held by Corvex and 40 North, currently owns approximately 50.1 million shares or 15.1% of Clariant AG ("Clariant"), making it the company's largest shareholder. As you know, we have attempted to work constructively with you and your advisors over the past two months, out of the public spotlight, to better understand the Board's questionable logic in pursuing Clariant's proposed merger with the Huntsman Corporation ("Huntsman"). Unfortunately, we remain convinced, and increasingly so, that the proposed merger is detrimental to Clariant shareholders. It both significantly destroys existing Clariant shareholder value and prevents Clariant from pursuing multiple alternative and immediate opportunities to unlock value for its shareholders.
 

To be clear:

1. The proposed transaction has no strategic merit and is a complete reversal of your own publicly-stated strategy of becoming a pure-play specialty chemicals company. After a decade of transforming Clariant's portfolio toward higher-margin specialty products, you would immediately undo all of that work by taking Clariant back to being an unfocused and commodity-oriented business with increased volatility and a lower market multiple. This runs counter to both your own stated goals for the company and industry trends toward specialization.

2. The terms of the proposed merger significantly undervalue Clariant's shares while they simultaneously overvalue Huntsman at the peak of its cyclical commodity business cycle.

3. The Board plans to cede operational control of one of the industry's most prized specialty chemicals companies for no control premium to Huntsman's management, demonstrating a severe lack of due diligence with regard to Huntsman's operational track record.

4. The company's rationale for the transaction appears to be adding scale for scale's sake and relying completely on the resulting cost synergies. We believe that approximately CHF 300 million of the ambitious CHF 400 million in potential cost synergy could be achieved by Clariant alone through a robust cost optimization plan without giving away nearly half of that value to Huntsman shareholders.


By all accounts, it does not appear that the Board seriously explored alternative measures or transactions to maximize shareholder value in advance of agreeing to merge with Huntsman, despite numerous credible reports of strategic interest in both parts of and in all of Clariant's business. In particular, and by your own admission, the company can immediately and accretively sell its Plastics and Coatings business at an attractive valuation with minimal tax leakage. This would be consistent with the strategy of becoming a pure-play specialty chemicals company and leave Clariant with maximum financial capacity to re-invest in its core specialty business without forgoing any strategic options. Stating that the combined Clariant and Huntsman would do just this following the merger defies basic rational business principles, as it would give away nearly half of this enormous value creation opportunity to Huntsman without fair consideration.

No shareholder should be asked to approve this merger without the Board's full exploration of avenues to maximize shareholder value. With this in mind, we call on the Board to work closely with White Tale and to immediately hire an independent investment bank to evaluate all strategic alternatives and simultaneously continue down the path of transformation to become a pure-play specialty chemicals company with a new and robust cost optimization plan. If such actions require Huntsman's consent under the existing agreement, the Board should seek to obtain it without delay. Without this exploration of alternatives, we will be forced to vote against the merger and, assuming the merger is voted down, we will insist that the exploration of alternatives - something that should have occurred prior to agreeing to the merger - begin promptly at that time.

We are prepared to work constructively with the company and its advisers, in a manner consistent with your obligations, including by serving on the Board of Directors, in order to achieve these goals. However, the Board now must finally undertake a full and disinterested review of all available opportunities to create shareholder value - something that has not happened to date.

Regards,


David J. Millstone David S. WinterCo-CIO of 40North Co-CIO of 40North
Co-CEO of Standard Industries Co-CEO of Standard Industries

Keith A. MeisterManaging Partner, Corvex Management


Zusatzmaterial zur Meldung:Dokument: http://n.eqs.com/c/fncls.ssp?u=EVFMHWQFGVDokumenttitel: Open Letter to Clariant
Ende der Medienmitteilung



610741  19.09.2017 









Aktuelle Nachrichten aus der 4investors-Redaktion

20.06.2018 - Aumann: 300 Millionen Euro im Fokus
20.06.2018 - Patrizia Immobilien: Zahlen stützen Prognose
20.06.2018 - Dr. Hönle: Prognose wird angehoben
20.06.2018 - Beate Uhse wird zu be you
20.06.2018 - E.On: Neue Möglichkeiten für das virtuelle Kraftwerk
20.06.2018 - Evotec: Baldiges Aus für die AG
20.06.2018 - Volkswagen: Ein Schritt in Richtung Kapitalmarktfähigkeit
20.06.2018 - DF Deutsche Forfait: Iran-Sanktionen haben schwerwiegende Folgen
20.06.2018 - Kulmbacher Brauerei: Späte Personalmeldung
20.06.2018 - Uhr.de: Details zur Kapitalerhöhung


Chartanalysen

20.06.2018 - Heidelberger Druck Aktie: Lichtblick am Mittwochmorgen, aber…
20.06.2018 - Dialog Semiconductor Aktie: Ein entscheidender Tag?
20.06.2018 - Geely Aktie: Diese Marke hat es in sich!
20.06.2018 - Commerzbank Aktie: Bärenfalle? Das könnte die Chance sein…
19.06.2018 - Medigene Aktie: Boden in Sicht?
19.06.2018 - Deutsche Bank Aktie: Befreiungsschlag voraus?
19.06.2018 - Heidelberger Druck Aktie: War das der Selloff? So sieht die Lage aus!
19.06.2018 - Steinhoff Aktie: Es wird richtig eng für den Konzern!
19.06.2018 - Evotec Aktie: Enttäuschung nach Sanofi-Deal
18.06.2018 - E.On Aktie: Das wäre eine nette Überraschung…


Analystenschätzungen

20.06.2018 - artec: Aktie mit neuem Kursziel
20.06.2018 - ThyssenKrupp: Positive Auswirkungen
20.06.2018 - K+S: Aktie weiter mit Kaufvotum
20.06.2018 - Volkswagen: Überraschende Entwicklung
20.06.2018 - Continental: Kommt ein Börsengang?
20.06.2018 - Roche: Sinnvolle Übernahme
20.06.2018 - Dialog Semiconductor: Apple-Abhängigkeit kann kleiner werden
20.06.2018 - Heidelberger Druckmaschinen: Verkaufsempfehlung für die Aktie entfällt
20.06.2018 - Volkswagen: Ein Minus von fast 10 Prozent
20.06.2018 - Daimler: Sorge um US-Zölle


Kolumnen

20.06.2018 - DAX 30 kurz vor wichtiger Hürde: Kaufsignal 200-Tage-Linie!? - Donner + Reuschel Kolumne
20.06.2018 - USA: Baugenehmigungen sinken im Mai, die Baubeginne steigen aber - Commerzbank Kolumne
20.06.2018 - EuroStoxx 50: Rallychance vertan - UBS Kolumne
20.06.2018 - DAX: Richtungsentscheidung sollte bald fallen - UBS Kolumne
18.06.2018 - DAX: „Dribbling“ auf der 13.000 - Wichtiger Test zum Wochenstart - Donner + Reuschel Kolumne
18.06.2018 - Tesla Aktie: Auf dem Weg zum Rekordhoch - UBS Kolumne
18.06.2018 - DAX: Noch haben die Bullen die Nase vorn - UBS Kolumne
15.06.2018 - DAX: „Die Spiele haben begonnen“ - Donner + Reuschel Kolumne
15.06.2018 - EUR/CHF: Abwärtstrend legt Pause ein - UBS Kolumne
15.06.2018 - DAX: Draghi lässt die Bullen jubeln - UBS Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR